News ArchivesRead News
Presynaptic Dopaminergic Lesion Predicts Drug-Induced Dyskinesia
Thursday May 15, 2014
Medwire News - Research suggests that the extent of presynaptic dopaminergic denervation before starting therapy may predict which patients with Parkinson’s disease (PD) will later develop levodopa-induced dyskinesia (LID).
Phil Lee (Yonsei University College of Medicine, Seoul, Korea) and colleagues studied 127 PD patients who underwent positron emission tomography at the time of diagnosis, before starting drug treatment.
They found that the larger the reduction patients had in dopamine transporter (DAT) uptake in the putamen at baseline, the higher was their risk of developing LID during an average 3.4 years of follow-up. This was true for the anterior, posterior and whole putamen after accounting for confounders, whereas DAT uptake in the caudate and ventral striatum did not predict LID.
When divided into tertiles based on DAT uptake, patients with moderate and severe reductions were respectively 2.97- and 3.47-fold more likely to develop LID relative to those with mild reductions.
The rate of LID in the whole cohort was 27.6% and the rate in those with mild DAT uptake reductions in the whole putamen was about 15% versus 50% in those with severe reductions.
In an editorial accompanying the study in Neurology, Peter LeWitt (Henry Ford Hospital, Bloomfield, Michigan, USA) and Maral Mouradian (Rutgers–Robert Wood Johnson Medical School, Piscataway, New Jersey, USA) say that the findings bring “presynaptic dopaminergic denervation into the forefront for explaining dyskinesia.”
However, they caution that there is as yet no “simple clinical message because of several confounding factors.”
These include a lower rate of dopaminergic agonist use among patients who developed LID, as well as a higher proportion of women. Patients with LID also had higher Unified Parkinson’s Disease Rating Scale scores at diagnosis and were taking a higher average daily levodopa dose.
Indeed, a higher levodopa dose was a significant predictor of LID on multivariate analysis, as was a younger age at PD onset.
“These confounding factors make it difficult to conclude how important the presynaptic dopaminergic lesion is, by itself, for developing LID”, conclude the editorialists.
(15 May 2014). Medwire News. Presynaptic Dopaminergic Lesion Predicts Drug-Induced Dyskinesia. http://www.medwirenews.com/454/105587/Parkinsons_disease/Presynaptic_dopaminergic_lesion_predicts_drug-induced_dyskinesia.html
Recent NewsMay 24 - Survival Rates Differ Widely in Parkinson's, MSA, Lewy Bodies
May 22 - Discovery may offer hope to Parkinson's disease patients
May 15 - Study offers answers on life expectancy for people with Parkinson's disease, Lewy body dementia
May 5 - Parkinson's in a dish: Researchers reproduce brain oscillations
May 5 - ‘Hunger Hormone’ Could Help Treat Parkinson’s Disease
May 3 - Antibiotic doxycycline may offer hope for treatment of Parkinson's disease
May 1 - Impulse Control Disorders in Parkinson's Disease: Building Physician, Patient Awareness
Apr 28 - Does Parkinson’s disease begin in the gut?
Apr 28 - New empathy-creating digital device could be revolutionary for caregivers
Apr 24 - Treating Depression With Deep Brain Stimulation Works—Most of the Time
Apr 24 - Parkinson’s disease shows links to depression
Apr 21 - TOLEDO Trial: Apomorphine Infusions Reduce 'Off' Time in Parkinson's Disease
Apr 21 - New drug provides long-awaited breakthrough for Parkinson's psychosis
Apr 12 - Obstructive Sleep Apnea Affects Cognition in Parkinson's Disease
Apr 11 - Seattle boxing gym giving hope to Parkinson's patients
Apr 10 - A new rhythm
Apr 10 - Brain cells reprogrammed to make dopamine, with goal of Parkinson's therapy
Apr 6 - FDA allows marketing of first direct-to-consumer tests that provide genetic risk information for certain conditions
Apr 5 - Combatting the isolation of young onset Parkinson's disease
Apr 1 - The Kid is Alright